Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1993 5
1994 3
1995 4
1996 3
1998 1
1999 3
2000 5
2001 6
2002 4
2003 4
2004 2
2005 1
2008 2
2010 1
2013 1
2014 1
2015 5
2016 3
2017 5
2018 6
2019 6
2020 1
2021 3
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Hughes DA, Culeddu G, Plumpton C, Wood E, Dick AD, Beresford MW, Ramanan AV. Hughes DA, et al. Among authors: plumpton c. Ophthalmology. 2019 Mar;126(3):e24-e25. doi: 10.1016/j.ophtha.2018.12.005. Ophthalmology. 2019. PMID: 30803529 No abstract available.
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Among authors: plumpton c. Lancet. 2021 Apr 10;397(10282):1375-1386. doi: 10.1016/S0140-6736(21)00246-4. Lancet. 2021. PMID: 33838758 Free PMC article. Clinical Trial.
The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton C, Hughes DA, Williamson P, Baker GA, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE; SANAD II collaborators. Marson A, et al. Among authors: plumpton c. Lancet. 2021 Apr 10;397(10282):1363-1374. doi: 10.1016/S0140-6736(21)00247-6. Lancet. 2021. PMID: 33838757 Free PMC article. Clinical Trial.
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Marson AG, et al. Among authors: plumpton co. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. Health Technol Assess. 2021. PMID: 34931602 Free article. Clinical Trial.
76 results